1. Home
  2. AG vs CYTK Comparison

AG vs CYTK Comparison

Compare AG & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Majestic Silver Corp. (Canada)

AG

First Majestic Silver Corp. (Canada)

N/A

Current Price

$26.84

Market Cap

10.2B

ML Signal

N/A

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$63.32

Market Cap

7.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AG
CYTK
Founded
1979
1997
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
7.6B
IPO Year
2004
2004

Fundamental Metrics

Financial Performance
Metric
AG
CYTK
Price
$26.84
$63.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
18
Target Price
$21.92
$87.56
AVG Volume (30 Days)
20.1M
1.7M
Earning Date
01-01-0001
05-25-2026
Dividend Yield
0.09%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$13,368,000.00
Revenue This Year
$13.75
$9.79
Revenue Next Year
$26.43
$302.66
P/E Ratio
$143.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.19
$29.31
52 Week High
$32.00
$70.98

Technical Indicators

Market Signals
Indicator
AG
CYTK
Relative Strength Index (RSI) 52.86 50.66
Support Level $20.21 $59.25
Resistance Level $27.90 $65.93
Average True Range (ATR) 1.81 2.54
MACD -0.49 -0.34
Stochastic Oscillator 43.01 41.35

Price Performance

Historical Comparison
AG
CYTK

About AG First Majestic Silver Corp. (Canada)

First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: